| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6458924 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
| US7235627 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
| US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 8 months ago) | |
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(2 years ago) | |
| US8846618 | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Jun, 2022
(1 year, 9 months ago) | |
|
US8846618 (Pediatric) | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Dec, 2022
(1 year, 3 months ago) | |
|
US6268343 (Pediatric) | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Feb, 2023
(1 year, 2 months ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
|
US8579869 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(3 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(27 days from now) | |
|
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(6 months from now) | |
|
US8114833 (Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(1 year, 9 months from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
|
US9265893 (Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(8 years from now) | |
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
|
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(13 years from now) | |
Victoza is owned by Novo Nordisk Inc.
Victoza contains Liraglutide Recombinant.
Victoza has a total of 20 drug patents out of which 12 drug patents have expired.
Expired drug patents of Victoza are:
- US6004297
- USRE43834
- USRE41956
- USRE41956*PED
- US8846618
- US8846618*PED
- US6268343*PED
- US8579869
- US8579869*PED
- US6458924
- US7235627
- US6268343
Victoza was authorised for market use on 25 January, 2010.
Victoza is available in solution;subcutaneous dosage forms.
Victoza can be used as method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide, a method for improving glycemic control in adults with type 2 diabetes mellitus.
Drug patent challenges can be filed against Victoza from 17 December, 2021.
The generics of Victoza are possible to be released after 09 July, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-176) | Apr 22, 2019 |
| New Patient Population(NPP) | Jun 17, 2022 |
| New Indication(I-750) | Aug 25, 2020 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
| M(M-115) | Apr 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US6268343 | NA | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 8 months ago) |